New combo therapy shows promise for myeloma relapse after transplant

This study tested a two-step treatment for people whose multiple myeloma returned after a donor stem cell transplant. First, patients received lenalidomide and dexamethasone to reduce cancer and prepare the immune system. Then, they received donor immune cells (lymphocyte infusions) to boost the body's ability to fight the cancer. The goal was to improve disease control and delay progression, while monitoring side effects like graft-versus-host disease. Ten adults aged 18-65 participated.